GAMMA Investing’s Spyre Therapeutics SYRE Stock Holding History

GAMMA Investing’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$73.5K	Buy	825 +162	+24%	+$15.6K	﹤0.01%	2101
2026 Q2	$58.9K	Buy	663 +140	+27%	+$10.2K	﹤0.01%	2192
2026 Q1	$26.4K	Buy	523 +193	+58%	+$7.28K	﹤0.01%	2571
2025 Q4	$10.8K	Buy	330 +122	+59%	+$3.19K	﹤0.01%	2939
2025 Q3	$3.49K	Buy	208 +34	+20%	+$554	﹤0.01%	3305
2025 Q2	$2.6K	Sell	174 -96	-36%	-$1.42K	﹤0.01%	3327
2025 Q1	$4.36K	Buy	+270	New	+$5.62K	﹤0.01%	3138
2024 Q4	–	Sell	-5	Closed	-$147	–	3825
2024 Q3	$147	Buy	+5	New	+$139	﹤0.01%	3541

Other funds holding SYRE

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's SYRE Position: Q3 2026 in Review

GAMMA Investing increased its Spyre Therapeutics (SYRE) stake by 24% in Q3 2026, buying an estimated $15.6K and bringing the position to 825 shares worth $73.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

GAMMA Investing first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. 2 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

GAMMA Investing held 825 shares of Spyre Therapeutics worth $73.5K as of Q3 2026.
GAMMA Investing bought 162 Spyre Therapeutics shares in Q3 2026, an estimated $15.6K.
Spyre Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2101 holding.
GAMMA Investing first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
2 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.